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The availability of a simple, sensitive, and rapid test using whole blood to facilitate processing and to reduce the turnaround time
could improve the management of patients presenting with chest pain. The aim of this study was an evaluation of the Innotrac
Aio! second-generation cardiac troponin I (cTnI) assay. The Innotrac Aio! second-generation cTnI assay was compared with the
Abbott AxSYM ﬁrst-generation cTnI, Beckman Access AccuTnI, and Innotrac Aio! ﬁrst-generation cTnI assays. We studied serum
samples from 15 patients with positive rheumatoid factor but with no indication of myocardial infarction (MI). Additionally,
the stability of the sample with diﬀerent matrices and the inﬂuence of hemodialysis on the cTnI concentration were evaluated.
Within-assay CVs were 3.2%–10.9%, and between-assay precision ranged from 4.0% to 17.2% for cTnI. The functional sensitivity
(CV = 20%) and the concentration giving CV of 10% were approximated to be 0.02 and 0.04, respectively. The assay was found
to be linear within the tested range of 0.063–111.6µg/L. The correlations between the second-generation Innotrac Aio!, Access,
and AxSYM cTnI assays were good (r coeﬃcients 0.947–0.966), but involved diﬀerences in the measured concentrations, and the
biases were highest with cTnI at low concentrations. The second-generation Innotrac Aio! cTnI assay was found to be superior to
the ﬁrst-generation assay with regard to precision in the low concentration range. The stability of the cTnI level was best in the
serum, lithium-heparin plasma, and lithium-heparin whole blood samples (n = 10, decrease < 10% in 24 hours at +20◦Ca n da t
+4◦C). There was no remarkable inﬂuence of hemodialysis on the cTnI release. False-positive cTnI values occurred in the presence
of very high rheumatoid factor values, that is, over 3000U/L. The 99th percentile of the apparently healthy reference group was
≤ 0.03µg/L. The results demonstrate the very good analytical performance of the second-generation Innotrac Aio! cTnI assay.
Copyright © 2006 P. Hedberg et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Cardiac troponin I cTnI is a sensitive and speciﬁc marker of
acute coronary syndromes and myocardial damage. During
thepastfewyears,ithasbecomethemostpreferredbiochem-
ical marker of myocardial infarction. The consensus docu-
ment of the Joint European Society of Cardiology/American
College of Cardiology (ESC/ACC) and the American Heart
Association(AHA)givesspeciﬁcrecommendationsconcern-
ing the use of biomarkers for the detection of myocardial
infarction [1, 2]. To avoid misclassiﬁcation arising from as-
say imprecision, the consensus committee proposed that the
99th percentile reference limit should be measured with total
imprecision (CV) < 10%. The purpose of the current study
was to evaluate the performance of the second-generation
cardiac troponin I assay on the Innotrac Aio! immunoas-
say platform, to establish the cutoﬀ limit, and to investi-
gate cTnI release in rheumatoid arthritis and the inﬂuence
of hemodialysis on cTnI release.
2. MATERIALS AND METHODS
2.1. Samples
Lithium-heparin plasma samples (Terumo Venoject Lithium
Heparin, Cat. no. VP 050SHL, Terumo Europe N. V. Leuven,2 Journal of Automated Methods and Management in Chemistry
Belgium, with a total heparin concentration of 15.9IU/mL
of whole blood) for cTnI determinations were randomly
collected from the routine samples of chest pain patients
and from apparently healthy persons. For a comparison of
whole blood and plasma samples, an additional lithium-
heparin sample was taken for whole blood determination
in parallel with the routine plasma sample. For the 99th
percentile determination of healthy volunteers with dif-
ferent sample matrices, a lithium-heparin tube, an addi-
tional K2-EDTA anticoagulated tube (Becton Dickinson Va-
cutainer, Cat. no. 368856, Becton Dickinson Systems, Ply-
mouth, UK), and a serum tube (Terumo Venoject II, Cat.
no. VP-050SPZ, Terumo Europe NV, Leuven, Belgium) were
taken. EDTA plasma samples and serum samples were used
for the hemodialysis and rheumatoid arthritis studies, re-
spectively. In order to obtain the lithium-heparin plasma,
serum, or EDTA plasma samples, the whole blood tubes
were centrifuged at 2000g for 15 minutes. The supernatant
plasma, serum, and whole blood were either analyzed im-
mediately or stored at 4◦C for analysis within 8h. For long-
term storage, the plasma and serum samples were placed at
−20◦C. Before analysis, the frozen samples were thawed at
room temperature, mixed, and centrifuged to remove any
particulate material.
All the patients granted permission for additional blood
samplestobecollected,andthelocalhospitalethicscommit-
tee approved the study.
2.2. Analyticalmethods
cTnI analyses were made using the Innotrac Aio! analyzer
(Innotrac Diagnostics Oy, Turku, Finland), and compara-
tive analyses were made with the Abbott AxSYM system
(Abbott Laboratories, Diagnostic Division, Abbott Park, Ill,
USA) and Beckman Access (Beckman Coulter, Inc., Chaska,
Minn). The rheumatoid factor determinations were mea-
sured with Hitachi 911 (Roche Diagnostics GmbH, D-68298
Mannheim). The Hct of the whole blood samples was deter-
mined by Abbott Cell-Dyn 4000 (Abbott Laboratories, Diag-
nostic Division, Abbott Park, Ill, USA).
The Innotrac Aio! analyzer is a fully automated random-
access immunoanalyzer based on a universal all-in-one dry-
reagent concept [3, 4]. The physical dimensions of the satel-
lite version are weight 65kg, height 650mm, width 620mm,
and depth 500mm. The central version with the sample con-
veyor has a weight of 80.5kg and width of 875 mm. All
analyte-speciﬁc reagents are dry-coated onto the bottom of
the analyte cups, which are packed into analyte pens (12
cups/pen), and only the addition of the sample and the
generic assay buﬀer is required. To perform the assay, the
sampleandthebuﬀerare,undercontinuousshaking,washed
and dried, after which the signal of intrinsically ﬂuorescent
Europium lanthanide chelate is read from the dry surface.
The quantitative results are available within 18 minutes after
the addition of the sample. Calibration of the assays is done
whenever a new kit lot is taken into use. Each kit box con-
tains a bar code for reading the factory-deﬁned calibration
data, which are used as a lot-speciﬁc reference curve. When
theinstrumentdetectsanalytepenswithanewlotnumber,it
requests the system to load a corresponding calibration pen.
The calibration is then performed automatically.
2.3. Imprecision
Three whole blood and 3 plasma samples with variable cTnI
concentrations were used to test within-assay precision (n =
20 per run). Commercial controls (Quantimetrix Cardia-
sure, levels 1, 2, and 3, Quantimetrix Corporation, Redondo
Beach, Calif, USA) and a low serum pool were used to test
interassay precision. Interassay precision was determined by
analyzing duplicate control samples twice a day on 10 sepa-
rate days (n = 40).
2.4. Linearity
Dilution linearity was investigated by serial dilution of ﬁve
samples of known cTnI concentrations. All the samples were
diluted with the instrument buﬀer solution.
2.5. Comparisonofsamplematerialsandmethods
The ﬁrst comparative analyses of second-generation Inno-
trac Aio! cTnI assay, Beckman Access AccuTnI, and Ab-
bott AxSYM cTnI (ﬁrst-generation) were carried out with a
set of 91 lithium-heparin plasma samples. Lithium-heparin
whole blood, lithium-heparin plasma, and serum compar-
isons were carried out with 38 patient samples and the Aio!
analyzer.Thehematocrit(Hct)valueofeachlithium-heparin
whole blood sample was determined by Cell-Dyn 4000.
The second comparative analyses of the Innotrac Aio! ﬁrst-
generation, Innotrac Aio! second-generation, and AxSYM
cTnI assays were carried out with a total of 97 lithium-
heparin plasma samples.
2.6. Detectionlimit,functionalsensitivity,and
theconcentrationgivingCVof10%
To determine the lowest measurable concentration of the
Innotrac Aio! second-generation cTnI that could be distin-
guished from zero, 20 replicates of the zero calibrator were
analyzed. The detection limits were calculated by determin-
ing the mean concentration plus 3SD. Functional sensitiv-
ity (20% CV) and the concentration giving a 10% CV result
were determined by analyzing lithium-heparin plasma pools
serially diluted with instrument buﬀer 1-2 per day in dupli-
cates for 10 days (n = 30). The interassay precision value
obtained using a serum pool was also used for the determi-
nation of 10% and 20% CVs.
2.7. 99thpercentilereferencelimits
Samples for the 99th percentile determination were collected
from an apparently healthy reference group (median ages
43 and 44, and ranges 22–59 and 22–67 years for women
and men, resp.). The determinations were carried out us-
ing a total of 71 EDTA whole blood, 69 EDTA plasma, 120P. Hedberg et al. 3
lithium-heparin plasma, and 72 serum samples. In an oral
health interview, no participant reported any known current
or past history of coronary artery disease, cardiac-releated
medical condition, or other permanent medication. All the
volunteers, with the exception of the 47 participants in the
group assigned to lithium-heparin plasma collection, were
also checked by echocardiography and the normal echocar-
diography was found in all the checked volunteers. The 99th
percentile determination with lithium-heparin plasma was
also reported previously in Euromedlab 2003 by us (the
99th percentile of the apparently healthy reference group was
0.025µg/L (n = 187) [5]).
2.8. Samplestability
The sample stability studies were made with lithium-heparin
whole blood, lithium-heparin plasma, EDTA whole blood,
EDTA plasma, and serum samples. Samples were taken from
a total of 10 patients suﬀering from acute MI (diﬀerent du-
rations of chest pain) or cardiac surgery. The samples were
divided into three tubes. The tubes were kept at room tem-
perature, at +4◦Ca n da t−20◦C (not whole blood). The
cTnI concentrations from the samples kept at room temper-
ature were measured at 0.5h, 1h, 2h, 2.5h, 3h, 5h, 8h, and
24h after the ﬁrst measurement. The ﬁrst measurement was
made about 30 minutes after the venipuncture (serum about
45min). Sample stability at +4◦C was determined at 1h, 2h,
3h, 5h, 8h, and 24h after the ﬁrst measurement. The stabili-
ties of theserum, lithium-heparin plasma, and EDTA plasma
samples were determined by freezing and thawing the sam-
ples 3 times. These samples were kept at −20◦C for at least 24
hours, and the cTnI concentrations were measured after the
three freezing and thawing cycles. Before analysis, the frozen
samples were thawed at room temperature, mixed, and cen-
trifuged to remove any particulate material.
2.9. Inﬂuenceofhemodialysisandrheumatoidfactor
In these studies, we determined cTnI in 48 chronic renal fail-
ure patients before and after hemodialysis. The time between
the two determinations was about 4-5 hours. We determined
the cTnI concentrations in serum samples from 15 patients
with positive rheumatoid factor but with no indication of
myocardial infarction. cTnI was determined with the Inno-
trac Aio! and AxSYM analyzers in both studies.
2.10. cTnIproﬁlesofpatients
cTnI concentrations were determined on admission and at
diﬀerent time points after admission from 7 patients suﬀer-
ingfromacuteMI,5coronaryarterybypassgrafting(CABG)
patients, 1 myocarditis patient, and 2 patients without a di-
agnosis of acute MI, of whom one had collapsus, chronic
bronchitis, and liver tumour and the other spinal surgery
and arrhythmias. The cTnI proﬁles of these samples were
determined with Innotrac Aio!, Beckman Access, and Ab-
bott AxSYM. Additionally, the cTnI proﬁles of 12 patients
with acute MI, 9 patients with CABG, 1 with bypass surgery,
Table 1: Within-assay and interassay precision.
n = 20
Within-assay
CV% precision
Mean µg/L
Plasma sample 1 0.037 7.2
Plasma sample 2 0.30 3.2
Plasma sample 3 3.7 5.0
Whole blood 1 0.023 10.9
Whole blood 2 0.12 3.4
Whole blood 3 2.8 3.7
Interassay
CV% precision
Mean µg/L
Quantimetrix Cardiasure 1 (n = 40) 0.37 7.1
Quantimetrix Cardiasure 2 (n = 40) 1.3 4.2
Quantimetrix Cardiasure 3 (n = 40) 3.3 3.7
Serum pool (n = 40) 0.11 4.0
Plasma pool 1 (n = 30) 0.037 12.0
Plasma pool 2 (n = 30) 0.020 17.2
and 1 with cardiomyopathy obtained with Innotrac Aio! and
AxSYM were compared.
3. RESULTS
3.1. Analyticalperformance
The analytic detection limit of the assay was 0.007µg/L. The
precision data for pooled plasma, serum, and commercial
controlsareshownsummarizedinTable 1.Within-assayCVs
were 3.2%–10.9%, and between-assay precision ranged from
4.0% to 17.2%. The functional sensitivity (CV = 20%) and
the concentrate giving CV of 10% were approximately 0.02
and 0.04µg/L, respectively, according to the precision results
shown in Table 1 for patient pools. The cTnI concentration
corresponding to a 10% CV and the detection limit obtained
nearly conﬁrmed the earlier published data by Pagani et al.
[6].
The linearity in the tested range of 0.063–112µg/L for
cTnI was within acceptable limits. The recoveries for the dif-
ferent dilutions were 74%–107%.
Figure 1 shows the diﬀerences between the compared
methods, expressed as Deming regression curves, percent-
age of the average, and plotted against the method average.
The following correlations emerged between the assays: In-
notrac Aio! = 0.45×Access+0.03, R2 = 0.947 (n = 91, range
< 20µg/L with Aio!), Innotrac Aio! = 0.38 × Access + 0.01,
R2 = 0.784 (n = 55, range < 0.5µg/L with Aio!), Innotrac
Aio! = 0.06 × AxSYM + 0.11, R2 = 0.966 (n = 91, range <
20µg/LwithAio!),andInnotracAio! = 0.05×AxSYM−0.01,
R2 = 0.588 (n = 55, range < 0.5µg/L with Aio!). The mean
diﬀerences (95% conﬁdence interval) for Aio! and Access
cTnI and for Aio! and AxSYM cTnI were 78% and 155%,
respectively.4 Journal of Automated Methods and Management in Chemistry
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Figure 1: Correlation between Access Li-heparin plasma and Innotrac Aio! second-generation cTnI Li-heparin plasma, and AxSYM Li-
heparin plasma and Innotrac Aio! second-generation cTnI Li-heparin plasma evaluated as Deming regression and plots of diﬀerences.
Percentage of diﬀerence (y-axis) = [method A-method B/average of the two methods] ×100. CI = conﬁdence interval.
The 99th percentiles of the healthy reference group with
diﬀerent sample matrices were all ≤ 0.03µg/L. These results
conﬁrm our previous ﬁndings and Pagani et al.’s results sug-
gesting that the 99th percentile limit could be at 0.03µg/L
[5, 6].
The analytical characteristics of cardiac troponin as re-
ported by the manufacturers are 0.04 for Access and 0.3µg/L
forAxSYMas99thpercentiles,whiletheCVsof10%are0.06
for Access and 0.8µg/L for AxSYM. Based on the 99th per-
centiles as a threshold value of the Access, AxSYM, and In-
notrac Aio! second-generation cTnI assays, 14 samples from
patients (from the total of 91, the clinical background was
checked from all of them) were classiﬁed diﬀerently into
following diagnostic categories: acute myocardial infarction,
unstable angina pectoris, prolonged angina pectoris, non-
ischemic chest pain, dyspnoe, coronary procedures (PTCA,
CABG), congestive hearth failure, and others (infections,
abdominal pain, pulmonary embolism, collapsus). When
the CV of 10% was used as a threshold value, 29 patients
were classiﬁed diﬀerently. In the second comparative study
(n = 97), discrepancies between the results obtained by us-
ing the 99th percentile limit and the 10% total CV concen-
tration limit in the AxSYM, Innotrac Aio! ﬁrst- and second-
generation cTnI assays were in seen in 8 samples and 17
samples, respectively. These patient groups were too limited
toallowanydetailedconclusionsregardingdiagnosticssensi-
tivity and speciﬁcity but allow conclusions in a broader sense
as to relative diagnostic performance of the compared assays.
The second-generation Aio! assay was found to be superior
to ﬁrst-generation assay.
The sample matrix correlation study using lithium-hep-
arin whole blood, lithium-heparin plasma, and serum sam-
ples yielded the following results: the slopes were lithium-
heparinplasma = 0.90×lithium-heparin whole blood−0.02,
R2 = 0.998 and serum = 1.08 × lithium-heparin plasma −
0.01, R2 = 0.997.
3.2. Samplestability
The level of cTnI in the serum, lithium-heparin plasma, and
lithium-heparin whole blood samples (n = 10) was found
to decrease from the original concentration less than 10% in
2 4h o u r sa tr o o mt e m p e r a t u r e ,e x c e p ta to n et i m ep o i n t ,3
hours, where the cTnI level in whole blood showed a 13%
decrease. The cTnI level in EDTA whole blood and EDTA
plasma decreased less than 10% in up to 1 hour and 1.5
hours, respectively. cTnI concentration at +4◦C decreased
less than 10% in all the matrices in 24 hours, except in EDTAP. Hedberg et al. 5
whole blood. Analyte concentration at −20◦C decreased less
than 10% in serum and lithium-heparin plasma, when freez-
ing and thawing cycles were done, but cTnI level in EDTA
plasma decreased more than 10% after one freeze-thaw cy-
cle.
3.3. Inﬂuenceofhemodialysisorrheumatoidfactor
The study group consisted of 48 patients treated with
hemodialysis (22 men and 26 women). The mean age of the
patients was 57 years (range: 15–89 years). Samples were ob-
tained before and after hemodialysis (n = 96). cTnI was
measuredfromEDTAplasmasampleswiththeInnotracAio!
andAxSYManalyzers.Theconcentrationrangeswere0.000–
0.039µg/Land0.0–1.1withtheAio!andAxSYMcTnIassays,
respectively.
In the hemodialysis study, a total of 3 patient sam-
ples were above the 99th percentile limit (0.039, 0.040,
and 0.035µg/L), and only one patient had a plasma level
above that cutoﬀ limit at both measurements (0.039 and
0.040µg/L). During hemodialysis session the cTnI values of
21/48 patients (43%) increased, while no change in cTnI val-
ues was seen in 15/48 patients (32%), and cTnI values of
12/48 patients (25%) decreased. However, the changes were
not signiﬁcant and may be due to the higher precision near
the detection limit and to the background signal. Addition-
ally, 2 of the samples were at the cutoﬀ limit.
Altogether,5sampleswereabovethe99thpercentilelimit
(0.9, 0.9, 1.1, 0.5, and 0.6µg/L), and two patients had both of
these values above the cutoﬀ limit (0.9/0.9 and 0.5/0.6µg/L)
using AxSYM assay. Additionally, 5 of the samples had con-
centration values at the cutoﬀ. During hemodialysis session
4/48 patients (8%) had increase in cTnI values, 7/48 patients
(15%) showed no change, and 37/48 patients (77%) had de-
crease in cTnI values. In conclusion, based on these results,
the positive cTnI results appear to be due to the coronary
artery disease of other potential injuries to the heart and
not due to the hemodialysis. Additionally, the imprecision of
> 10% CV at the 99th percentile of the reference group does
not permit reliable determination of cTnI at this concentra-
tion with these methods.
False-positive troponin I values due to the presence
of rheumatoid factor have been described [7]. We studied
serum samples from 15 rheumatoid patients. The rheuma-
toid factors (RFs) measured using Hitachi 911 varied from
20 to 3630U/L. Only one of the samples had a cTnI con-
centration (0.070µg/L) above the 99th percentile with a very
high RF concentration of 3630U/L. This sample needs to be
further investigated. The concentrations of cTnI in serum
samples were also measured using the AxSYM analyzer. No
measurable cTnI was observed in these samples with this an-
alyzer.
3.4. DifferencesincTnIproﬁlesbetweenthemethods
The total of 38 patient proﬁles with diﬀerent cardiac events
using diﬀerent commercial methods were determined. The
proﬁles were similar, but in the 2/3 comparisons with
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Figure 2: An example of cTnI proﬁles of patients with acute MI.
TheInnotracAio!second-generationassayisindicatedasalinewith
fulled circles, Abbott AxSYM as a line with boxes, and Beckman Ac-
cess AccuTnI as a line with triangles. The 10% total CV concentra-
tion limits (µg/L) of the methods are marked as horizontal lines.
second-generation Innotrac Aio!, AxSYM, and Access meth-
ods, the second-generation Innotrac Aio! and Access assays
detected the released cTnI and myocardial damage earlier
thantheAxSYMassay.Figure 2showsanexampleoftheAMI
patient’s proﬁle using the Innotrac Aio! second-generation
assay in comparison with the commercial assays.
4. DISCUSSION
The complex molecular nature of cTnI complicates mea-
surement by immunoassays, causing the commercial assays
to detect cTnI diﬀerently. The diﬀerences between the re-
sults can be explained by the use of diﬀerent antibodies in
the assays, the lack of international standardization and het-
erophilic antibodies, which may cause false-positive results
in immunoassays. The diﬀerent distributions of cTnI forms
in the early versus late phase of myocardial infarction may
explain the diﬀerences. It has been shown that, in addition to
occuring as free cTnI and in binary complexes with TnI and
TnT, TnI may exist in phosphorylated, oxidized, and pro-
teolytically degraded forms [8]. They can change the struc-
ture and conformation of the molecule and thereby aﬀect
the antibody- antigen interaction [9]. It has also been shown
that troponin is released into the bloodstream of patients
with acute myocardial infarction not in a free form but as
ac o m p l e x[ 10]. The antibodies used in the assays should
ideally recognize equally both free and complexed forms. It
has been recommended that the antibodies used for the de-
velopment of reliable cardiac troponin assays should prefer-
ably recognize epitopes that are located in the stable part of
the molecule and are not aﬀected by complex formation and
other in vivo modiﬁcations [11].
Previously, Eriksson et al. [12] evaluated the presence of
interfering factors in cTnI assays by measuring the recov-
ery of cTnI added to samples from volunteers and from pa-
tients with acute coronary syndromes. The factor may cause6 Journal of Automated Methods and Management in Chemistry
variable inhibition of cTnI immunoreactivity, from mild to
very severe, depending on the amount of interfering factor
in the sample. The interfering factor had the greatest eﬀect
on cTnI measurements when there were only small amounts
of cTnI present in the sample, as in the early hours of an MI
or unstable angina event. Eriksson et al. proposed as a solu-
tion to the problem a multi-antibody assay, in which the an-
tibodycombinationsarechosenfromtheterminalpartswith
a mid-fragment part, because the most interference-free an-
tibodies are those against epitopes in the terminal parts of
the molecule, which are not present in the fragmented cTnI
molecules. According to the manufacturer, the Innotrac Aio!
second-generation assay has been developed using this in-
formation. This may explain the earlier detection of released
cTnI and myocardial damage compared to the AxSYM as-
say as seen in Figure 2. The Access assay seemed to detect
the cTnI of MI patients equally early as the Aio! assay, thus
showing that the antibodies may have been chosen from the
same regions. The clearly improved performance of the Aio!
second-generation assay compared to the ﬁrst-generationas-
say near the cutoﬀ limit could be explained partly by the
new antibodies used in the assay. The lack of reproducibil-
ity (CV% > 10) by AxSYM at very low concentrations could
also explain the lack of correlation between the assays at low
levels [13, 14]. On the other hand, Abbott has recently in-
troduced a second-generation cTnI assay using AxSYM ana-
lyzer.
The deﬁnition of MI by international cardiology as-
sociations led to a further reduction of the cutoﬀ values.
To avoid misclassiﬁcation arising from assay imprecision,
the consensus committee proposed that the 99th percentile
reference limit should be measured with total imprecision
(CV) < 10%. The imprecision of the Innotrac Aio! second-
generation assay was highly superior to that of the previously
published ﬁrst-generation assay [15]. In our precision study,
theratio10%CV/99thwas1.3,provingthegoodimprecision
of the assay.
Plasmahasbeenrecommendedasthespecimenofchoice
by both the cardiology and the laboratory medicine com-
munities, to keep the turnaround time short [11]. How-
ever, there may be signiﬁcant diﬀerences between serum and
plasmaconcentrationsoftroponinswhendiﬀerentanalytical
systems are used [16]. According to our matrix comparison
data, lithium-heparin plasma, whole blood, and serum are
all acceptable matrices for the determination of cTnI with
the Aio! second-generation assay.
This study was a preliminary study showing the charac-
teristics of a new second-generation assay of cTnI on the In-
notrac Aio! Analyzer. To improve the statistics the number of
patients and controls should be higher.
The ability to work with whole blood samples provides a
great advantage, saving time and work, and if the follow-up
testing is carried out at a central laboratory, it is possible to
analyze serum and plasma by using the same system. Inno-
tracAio!isquickandeasytouseandmaintain,andthussuit-
able for use in emergency rooms, coronary care units, satel-
lite laboratories, and central laboratories.
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